Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Claudia, Paba-Prada"'
Autor:
Kenneth C. Anderson, Rolf Lewensohn, Paul Richardson, Nikhil Munshi, Claudia Paba-Prada, Jack Spira, Kristina Viktorsson, Arghya Ray, Dharminder Chauhan
PDF file - 66K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f065fa055a3e236872e0e0fbe91ecc
https://doi.org/10.1158/1078-0432.22450782.v1
https://doi.org/10.1158/1078-0432.22450782.v1
Autor:
Kenneth C. Anderson, Rolf Lewensohn, Paul Richardson, Nikhil Munshi, Claudia Paba-Prada, Jack Spira, Kristina Viktorsson, Arghya Ray, Dharminder Chauhan
PDF file - 4200K, Supplementary Figure 1 (A) MM.1R and RPMI-8226 MM cells were treated with mel-flufen {1μM and 3μM, respectively} for 24h; protein lysates were subjected to immunoblotting using indicated antibodies. (B) MM1.R cells were treated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4664a142383a40271726c0d6ab22d26
https://doi.org/10.1158/1078-0432.22450788.v1
https://doi.org/10.1158/1078-0432.22450788.v1
Autor:
Kenneth C. Anderson, Rolf Lewensohn, Paul Richardson, Nikhil Munshi, Claudia Paba-Prada, Jack Spira, Kristina Viktorsson, Arghya Ray, Dharminder Chauhan
Purpose: The alkylating agent melphalan prolongs survival in patients with multiple myeloma; however, it is associated with toxicities and development of drug-resistance. Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen), a novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043f5d243b76a4b14fe7ae82bde71b31
https://doi.org/10.1158/1078-0432.c.6522024.v1
https://doi.org/10.1158/1078-0432.c.6522024.v1
Autor:
Kenneth C. Anderson, Rolf Lewensohn, Paul Richardson, Nikhil Munshi, Claudia Paba-Prada, Jack Spira, Kristina Viktorsson, Arghya Ray, Dharminder Chauhan
PDF file - 281K, Supplementary Figure 2 MM.1S cells were treated with indicated concentrations of melphalan or mel-flufen for 4h. The cells were harvested and subjected to alkaline comet assay, and the fluorescent images were visualized (excitation/e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d03f0e6259525c159bcb45dbc91cf4b
https://doi.org/10.1158/1078-0432.22450785.v1
https://doi.org/10.1158/1078-0432.22450785.v1
Autor:
Matthew Ho, Maria Moscvin, Soon Khai Low, Benjamin Evans, Sara Close, Robert Schlossman, Jacob Laubach, Claudia Paba Prada, Brett Glotzbecker, Paul G. Richardson, Giada Bianchi
Publikováno v:
Leuk Lymphoma
Orthostatic hypotension (OH) is a well-recognized phenomenon occurring in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), and is associated with significant morbidity and mortality. A retrospective analysis of patien
Autor:
Paul G, Richardson, Susanna J, Jacobus, Edie A, Weller, Hani, Hassoun, Sagar, Lonial, Noopur S, Raje, Eva, Medvedova, Philip L, McCarthy, Edward N, Libby, Peter M, Voorhees, Robert Z, Orlowski, Larry D, Anderson, Jeffrey A, Zonder, Carter P, Milner, Cristina, Gasparetto, Mounzer E, Agha, Abdullah M, Khan, David D, Hurd, Krisstina, Gowin, Rammurti T, Kamble, Sundar, Jagannath, Nitya, Nathwani, Melissa, Alsina, R Frank, Cornell, Hamza, Hashmi, Erica L, Campagnaro, Astrid C, Andreescu, Teresa, Gentile, Michaela, Liedtke, Kelly N, Godby, Adam D, Cohen, Thomas H, Openshaw, Marcelo C, Pasquini, Sergio A, Giralt, Jonathan L, Kaufman, Andrew J, Yee, Emma, Scott, Pallawi, Torka, Amy, Foley, Mariateresa, Fulciniti, Kyle, Hebert, Mehmet K, Samur, Kelly, Masone, Michelle E, Maglio, Andrea A, Zeytoonjian, Omar, Nadeem, Robert L, Schlossman, Jacob P, Laubach, Claudia, Paba-Prada, Irene M, Ghobrial, Aurore, Perrot, Philippe, Moreau, Hervé, Avet-Loiseau, Michel, Attal, Kenneth C, Anderson, Nikhil C, Munshi, Hillard, Lazarus
Publikováno v:
N Engl J Med
BACKGROUND: In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until
Publikováno v:
Blood. 132:1114-1124
The treatment landscape for multiple myeloma has been transformed by the introduction of novel agents, including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. These have been shown to be more effective and generally better
Autor:
Gullu Gorgun, Michelle E. Maglio, Cindy Varga, Constantine S. Mitsiades, Irene M. Ghobrial, Noopur Raje, Anna Guidetti, Mary McKenney, Robert L. Schlossman, Claudia Paba Prada, Paul G. Richardson, Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Deborah Doss, Jacob P. Laubach
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1089-1108
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is uniq
Publikováno v:
Cancer treatment and research. 169
Survival outcomes of patients with Multiple Myeloma (MM) have improved over the last decade due to the introduction of novel agents such as the immunomodulatory drugs thalidomide, lenalidomide (Len) and pomalidomide, and the proteasome inhibitors bor
Autor:
Cara A. Rosenbaum, Andrzej Jakubowiak, Jacob P. Laubach, Paul G. Richardson, Claudia Paba Prada, Jagoda Jasielec
Publikováno v:
Seminars in Oncology. 40:592-601
Until the advents of novel agents, partial response (PR) or better was the established gold standard to initial therapy of multiple myeloma (MM), and treatment goals were focused on relieving symptoms, prevention of organ damage, and modest improveme